The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.
Bispecific antibodies: design, therapy, perspectives
Open accessAbstract
Antibodies (Abs) containing two different antigen-binding sites in one molecule are called bispecific. Bispecific Abs (BsAbs) were first described in the 1960s, the first monoclonal BsAbs were generated in the 1980s by hybridoma technology, and the first article describing the therapeutic use of BsAbs was published in 1992, but the number of papers devoted to BsAbs has increased significantly in the last 10 years. Particular interest in BsAbs is due to their therapeutic use. In the last decade, two BsAbs - catumaxomab in 2009 and blinatumomab in 2014, were approved for therapeutic use. Papers published in recent years have been devoted to various methods of BsAb generation by genetic engineering and chemical conjugation, and describe preclinical and clinical trials of these drugs in a variety of diseases. This review considers diverse BsAb-production methods, describes features of therapeutic BsAbs approved for medical use, and summarizes the prospects of practical application of promising new BsAbs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two new Later Stone Age sites from the Final Pleistocene in the Falémé Valley, eastern Senegal
Ndiaye, M., Lespez, L., Tribolo, C., Rassé, M., Hadjas, I., Davidoux, S., Huysecom, É., & Douze, K. (2024) · Monash University Research Portal (Monash University) · doi:10.3929/ethz-b-000667478 · Cited by 23,868
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Therapeutic antibodies: successes, limitations and hopes for the future
Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00190.x · Cited by 1,382
Topp, M. S., Gökbuget, N., Stein, A. S., Zugmaier, G., O'Brien, S., Bargou, R. C., Dombret, H., Fielding, A. K., Heffner, L., Larson, R. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71170-2 · Cited by 1,269
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., et al. (2008) · Science · doi:10.1126/science.1158545 · Cited by 1,078
Biopharmaceutical benchmarks 2014
Walsh, G. (2014) · Nature Biotechnology · doi:10.1038/nbt.3040 · Cited by 1,008
Ward, E. S., Güssow, D., Griffiths, A. D., Jones, P. T., & Winter, G. (1989) · Nature · doi:10.1038/341544a0 · Cited by 1,003
Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange
van der Neut Kolfschoten, M., Schuurman, J., Losen, M., Bleeker, W. K., Martínez-Martínez, P., Vermeulen, E., den Bleker, T. H., Wiegman, L., Vink, T., Aarden, L. A., et al. (2007) · Science · doi:10.1126/science.1144603 · Cited by 975
The making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 923
Topp, M. S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.-A., Raff, T., Viardot, A., Schmid, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7270 · Cited by 913
"Diabodies": small bivalent and bispecific antibody fragments.
Holliger, P., Prospero, T., & Winter, G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6444 · Cited by 874
‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization
Ridgway, J. B. B., Presta, L. G., & Carter, P. (1996) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/9.7.617 · Cited by 810
Biopharmaceutical benchmarks 2010
Walsh, G. (2010) · Nature Biotechnology · doi:10.1038/nbt0910-917 · Cited by 756
Aalberse, R. C., van der Gaag, R., & van Leeuwen, J. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.130.2.722 · Cited by 736
Topp, M. S., Gökbuget, N., Zugmaier, G., Klappers, P., Stelljes, M., Neumann, S., Viardot, A., Marks, R., Diedrich, H., Faul, C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.3247 · Cited by 658
Alternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607
Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Baeuerle, P. A., & Reinhardt, C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0547 · Cited by 592
Kontermann, R. E., & Brinkmann, U. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.008 · Cited by 578
Heiss, M. M., Murawa, P., Koralewski, P., Kutarska, E., Kolesnik, O. O., Ivanchenko, V. V., Dudnichenko, A. S., Aleknaviciene, B., Razbadauskas, A., Gore, M., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25423 · Cited by 549
Genovese, M. C., Cohen, S., Moreland, L., Lium, D., Robbins, S., Newmark, R., Bekker, P., & for the 20000223 Study Group (2004) · Arthritis & Rheumatism · doi:10.1002/art.20221 · Cited by 532
Hybrid hybridomas and their use in immunohistochemistry
Milstein, C., & Cuello, A. C. (1983) · Nature · doi:10.1038/305537a0 · Cited by 517
Hybrid antibodies can target sites for attack by T cells
Staerz, U. D., Kanagawa, O., & Bevan, M. J. (1985) · Nature · doi:10.1038/314628a0 · Cited by 492
Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A
Shima, M., Hanabusa, H., Taki, M., Matsushita, T., Sato, T., Fukutake, K., Fukazawa, N., Yoneyama, K., Yoshida, H., & Nogami, K. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1511769 · Cited by 478
Topp, M. S., Gökbuget, N., Zugmaier, G., Degenhard, E., Goebeler, M.-E., Klinger, M., Neumann, S. A., Horst, H. A., Raff, T., Viardot, A., et al. (2012) · Blood · doi:10.1182/blood-2012-07-441030 · Cited by 474
Klinger, M., Brandl, C., Zugmaier, G., Hijazi, Y., Bargou, R. C., Topp, M. S., Gökbuget, N., Neumann, S., Goebeler, M., Viardot, A., et al. (2012) · Blood · doi:10.1182/blood-2012-01-400515 · Cited by 471
Löffler, A., Kufer, P., Lutterbüse, R., Zettl, F., Daniel, P. T., Schwenkenbecher, J. M., Riethmüller, G., Dörken, B., & Bargou, R. C. (2000) · Blood · doi:10.1182/blood.v95.6.2098 · Cited by 445
Dual targeting strategies with bispecific antibodies
Kontermann, R. (2012) · mAbs · doi:10.4161/mabs.4.2.19000 · Cited by 435
Monoclonal Antibodies for Cancer Therapy
(2012) · SpringerReference · doi:10.1007/springerreference_303431 · Cited by 393
Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates
Yu, Y. J., Atwal, J. K., Zhang, Y., Tong, R. K., Wildsmith, K. R., Tan, C., Bien-Ly, N., Hersom, M., Maloney, J. A., Meilandt, W. J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009835 · Cited by 371
Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site
Bostrom, J., Yu, S.-F., Kan, D., Appleton, B. A., Lee, C. V., Billeci, K., Man, W., Peale, F., Ross, S., Wiesmann, C., et al. (2009) · Science · doi:10.1126/science.1165480 · Cited by 370
Baker, K. F., & Isaacs, J. D. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211555 · Cited by 370
Mack, M., Riethmüller, G., & Kufer, P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.7021 · Cited by 351 · cited 1×
“BiTEs usually contain an antigenbinding site against CD3 and another against a high-affinity surface antigen of tumor cells.(44,112,113) A disadvantage of such molecules is their short life span in blood serum, which is associated with smallness and lack of Fc.”
Dreier, T., Lorenczewski, G., Brandl, C., Hoffmann, P., Syring, U., Hanakam, F., Kufer, P., Riethmuller, G., Bargou, R., & Baeuerle, P. A. (2002) · International Journal of Cancer · doi:10.1002/ijc.10557 · Cited by 348
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin
Wu, C., Ying, H., Grinnell, C., Bryant, S., Miller, R., Clabbers, A., Bose, S., McCarthy, D., Zhu, R.-R., Santora, L., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1345 · Cited by 344
Schaefer, G., Haber, L., Crocker, L. M., Shia, S., Shao, L., Dowbenko, D., Totpal, K., Wong, A., Lee, C. V., Stawicki, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.003 · Cited by 341
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
Labrijn, A. F., Meesters, J. I., de Goeij, B. E. C. G., van den Bremer, E. T. J., Neijssen, J., van Kampen, M. D., Strumane, K., Verploegen, S., Kundu, A., Gramer, M. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220145110 · Cited by 339
Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody
Perez, P., Hoffman, R. W., Shaw, S., Bluestone, J. A., & Segal, D. M. (1985) · Nature · doi:10.1038/316354a0 · Cited by 337
Rothe, A., Sasse, S., Topp, M. S., Eichenauer, D. A., Hummel, H., Reiners, K. S., Dietlein, M., Kuhnert, G., Kessler, J., Buerkle, C., et al. (2015) · Blood · doi:10.1182/blood-2014-12-614636 · Cited by 337
Bispecific antibodies for cancer therapy: The light at the end of the tunnel?
Chames, P., & Baty, D. (2009) · mAbs · doi:10.4161/mabs.1.6.10015 · Cited by 336
Els Conrath, K., Lauwereys, M., Wyns, L., & Muyldermans, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007734200 · Cited by 300
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo
Labrijn, A. F., Buijsse, A. O., van den Bremer, E. T. J., Verwilligen, A. Y. W., Bleeker, W. K., Thorpe, S. J., Killestein, J., Polman, C. H., Aalberse, R. C., Schuurman, J., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1553 · Cited by 298
Seimetz, D., Lindhofer, H., & Bokemeyer, C. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.03.001 · Cited by 284
Recombination of a mixture of univalent antibody fragments of different specificity
Nisonoff, A., & Rivers, M. M. (1961) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(61)90296-x · Cited by 277
Catumaxomab: Clinical development and future directions
Linke, R., Klein, A., & Seimetz, D. (2010) · mAbs · doi:10.4161/mabs.2.2.11221 · Cited by 274
Glennie, M. J., McBride, H. M., Worth, A. T., & Stevenson, G. T. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.7.2367 · Cited by 263
Atwell, S., Ridgway, J. B. B., Wells, J. A., & Carter, P. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1116 · Cited by 261
A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair
Florio, M., Gunasekaran, K., Stolina, M., Li, X., Liu, L., Tipton, B., Salimi-Moosavi, H., Asuncion, F. J., Li, C., Sun, B., et al. (2016) · Nature Communications · doi:10.1038/ncomms11505 · Cited by 257
Brennan, M., Davison, P. F., & Paulus, H. (1985) · Science · doi:10.1126/science.3925553 · Cited by 251
Müller, D., Karle, A., Meißburger, B., Höfig, I., Stork, R., & Kontermann, R. E. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700820200 · Cited by 222
Lindhofer, H., Mocikat, R., Steipe, B., & Thierfelder, S. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.1.219 · Cited by 213 · cited 2×
“43 The application of catumaxomab in clinical trials and therapy proves to be successful, since there is no barrier for T lymphocytes or catumaxomab molecules to penetrating ascites tumors.”
Zhu, M., Wu, B., Brandl, C., Johnson, J., Wolf, A., Chow, A., & Doshi, S. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0405-4 · Cited by 211
Rossi, E. A., Goldenberg, D. M., Cardillo, T. M., McBride, W. J., Sharkey, R. M., & Chang, C.-H. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600982103 · Cited by 209
Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics
Kipriyanov, S. M., Moldenhauer, G., Schuhmacher, J., Cochlovius, B., Von der Lieth, C.-W., Matys, E. R., & Little, M. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3156 · Cited by 202
Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity
Huang, Y., Yu, J., Lanzi, A., Yao, X., Andrews, C. D., Tsai, L., Gajjar, M. R., Sun, M., Seaman, M. S., Padte, N. N., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.024 · Cited by 199
Walsh, G. (2000) · Nature Biotechnology · doi:10.1038/78720 · Cited by 198
Davis, J. H., Aperlo, C., Li, Y., Kurosawa, E., Lan, Y., Lo, K.-M., & Huston, J. S. (2010) · Protein Engineering, Design and Selection · doi:10.1093/protein/gzp094 · Cited by 194
BiTE: Teaching antibodies to engage T-cells for cancer therapy.
Baeuerle, P. A., Kufer, P., & Bargou, R. C. (2009) · PubMed · Cited by 192
Valone, F. H., Kaufman, P. A., Guyre, P. M., Lewis, L. D., Memoli, V, Deo, Y., Graziano, R., Fisher, J. L., Meyer, L., & Mrozek-Orlowski, M. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.9.2281 · Cited by 180
Mode of cytotoxic action of T cell-engaging BiTE antibody MT110
Haas, C., Krinner, E., Brischwein, K., Hoffmann, P., Lutterbüse, R., Schlereth, B., Kufer, P., & Baeuerle, P. A. (2009) · Immunobiology · doi:10.1016/j.imbio.2008.11.014 · Cited by 178
Shalaby, M. R., Shepard, H. M., Presta, L., Rodrigues, M. L., Beverley, P. C., Feldmann, M., & Carter, P. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.1.217 · Cited by 176
Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody
Ruf, P., & Lindhofer, H. (2001) · Blood · doi:10.1182/blood.v98.8.2526 · Cited by 174
Mechanisms of action of therapeutic antibodies for cancer
Redman, J. M., Hill, E. M., AlDeghaither, D., & Weiner, L. M. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.04.002 · Cited by 171
Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy
Goebeler, M.-E., & Bargou, R. (2016) · Leukemia & Lymphoma · doi:10.3109/10428194.2016.1161185 · Cited by 170
Wu, J., Fu, J., Zhang, M., & Liu, D. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0195-4 · Cited by 169
Targeting T cells to tumor cells using bispecific antibodies
Frankel, S. R., & Baeuerle, P. A. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.03.029 · Cited by 166
Aldoss, I., Song, J., Stiller, T., Nguyen, T., Palmer, J., O'Donnell, M., Stein, A. S., Marcucci, G., Forman, S., & Pullarkat, V. (2017) · American Journal of Hematology · doi:10.1002/ajh.24783 · Cited by 164
Bispecific antibodies in cancer therapy
Segal, D. M., Weiner, G. J., & Weiner, L. M. (1999) · Current Opinion in Immunology · doi:10.1016/s0952-7915(99)00015-1 · Cited by 161
A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications
Byrne, H., Conroy, P. J., Whisstock, J. C., & O’Kennedy, R. J. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.08.007 · Cited by 159
Recent advances of bispecific antibodies in solid tumors
Yu, S., Li, A., Liu, Q., Yuan, X., Xu, H., Jiao, D., Pestell, R. G., Han, X., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0522-z · Cited by 158
Structural and functional characterization of the trifunctional antibody catumaxomab
Chelius, D., Ruf, P., Gruber, P., Plöscher, M., Liedtke, R., Gansberger, E., Heß, J., Wasiliu, M., & Lindhofer, H. (2010) · mAbs · doi:10.4161/mabs.2.3.11791 · Cited by 152
The coming of age of engineered multivalent antibodies
Nuñez‐Prado, N., Compte, M., Harwood, S. L., Álvarez-Méndez, A., Lykkemark, S., Sanz, L., & Álvarez‐Vallina, L. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.013 · Cited by 151
Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency
Bournazos, S., Gazumyan, A., Seaman, M. S., Nussenzweig, M. C., & Ravetch, J. V. (2016) · Cell · doi:10.1016/j.cell.2016.04.050 · Cited by 150
Generating Bispecific Human IgG1 and IgG2 Antibodies from Any Antibody Pair
Strop, P., Ho, W.-H., Boustany, L. M., Abdiche, Y. N., Lindquist, K. C., Farias, S., Rickert, M., Appah, C. T., Pascua, E., Radcliffe, T., et al. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.04.020 · Cited by 148
Antibody VH Domains as Small Recognition Units
Davies, J., & Riechmann, L. (1995) · Nature Biotechnology · doi:10.1038/nbt0595-475 · Cited by 140
Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
Weiner, L. M., Clark, J. I., Davey, M., Li, W. S., de Palazzo, I. G., Ring, D. B., & Alpaugh, R. K. (1995) · PubMed · Cited by 139
Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
Freedman, J. D., Hagel, J., Scott, E. M., Psallidas, I., Gupta, A., Spiers, L., Miller, P. F., Kanellakis, N. I., Ashfield, R., Fisher, K. D., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707567 · Cited by 138
Reusch, U., Duell, J., Ellwanger, K., Herbrecht, C., Knackmuss, S. H. J., Fucek, I., Eser, M., McAleese, F., Molkenthin, V., Gall, F. L., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1029216 · Cited by 134
Chemical generation of bispecific antibodies
Doppalapudi, V. R., Huang, J., Liu, D., Jin, P., Liu, B., Li, L., Desharnais, J., van Hagen, C., Levin, N. J., Shields, M. J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016478108 · Cited by 124
The development of bispecific antibodies and their applications in tumor immune escape
Zhang, X., Yang, Y., Fan, D., & Xiong, D. (2017) · Experimental Hematology and Oncology · doi:10.1186/s40164-017-0072-7 · Cited by 122
Wu, J., Fu, J., Zhang, M., & Liu, D. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0188-3 · Cited by 117
Stork, R., Müller, D., & Kontermann, R. E. (2007) · Protein Engineering Design and Selection · doi:10.1093/protein/gzm061 · Cited by 111
Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide.
McBride, W. J., ZANZONICO, P. B., Sharkey, R. M., Norén, C., Karacay, H., Rossi, E. A., Losman, M. J., Brard, P.-Y., Chang, C., Larson, S. M., et al. (2006) · PubMed · Cited by 111
Translation and Clinical Development of Bispecific T‐cell Engaging Antibodies for Cancer Treatment
Yuraszeck, T. M., Kasichayanula, S., & Benjamin, J. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.651 · Cited by 103
Sebastian, M., Passlick, B., Friccius-Quecke, H., Jäger, M., Lindhofer, H., Kanniess, F., Wiewrodt, R. G., Thiel, E., Buhl, R., & Schmittel, A. H. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0310-7 · Cited by 100
Silacci, M., Lembke, W., Woods, R., Attinger-Toller, I., Bänziger-Tobler, N. E., Batey, S., Santimaria, R., von der Bey, U., Koenig-Friedrich, S., Zha, W., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1093266 · Cited by 95
Polyfunctional response by Imm TAC ( IMC gp100) redirected CD 8 + and CD 4 + T cells
Boudousquié, C., Bossi, G., Hurst, J. M., Rygiel, K. A., Jakobsen, B. K., & Hassan, N. J. (2017) · Immunology · doi:10.1111/imm.12779 · Cited by 94
Remodeling domain interfaces to enhance heterodimer formation
Zhu, Z., Presta, L. G., Zapata, G. A., & Carter, P. M. (1997) · Protein Science · doi:10.1002/pro.5560060404 · Cited by 87
Chang, C., Rossi, E. A., & Goldenberg, D. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1217 · Cited by 85
Bossi, G., Buisson, S., Oates, J., Jakobsen, B. K., & Hassan, N. J. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1525-z · Cited by 81
Hu, S., Fu, W., Xu, W., Yang, Y., Cruz, M., Berezov, S. D., Jorissen, D., Takeda, H., & Zhu, W. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1670 · Cited by 81
Alt, M., Müller, R., & Kontermann, R. E. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00782-6 · Cited by 77
Ott, M., Marmé, F., Moldenhauer, G., Lindhofer, H., Hennig, M., Spannagl, R., Essing, M. M., Linke, R., & Seimetz, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.26258 · Cited by 77
Clinical Pharmacology and Translational Aspects of Bispecific Antibodies
Trivedi, A., Stienen, S., Zhu, M., Li, H., Yuraszeck, T., Gibbs, J., Heath, T., Loberg, R., & Kasichayanula, S. (2017) · Clinical and Translational Science · doi:10.1111/cts.12459 · Cited by 76
Are BiTEs the “missing link” in cancer therapy?
Suryadevara, C. M., Gedeon, P. C., Sanchez-Perez, L. A., Verla, T. G., Alvarez-Breckenridge, C. A., Choi, B. D., Fecci, P. E., & Sampson, J. H. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008339 · Cited by 75
Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies
Yang, F., Wen, W., & Qin, W. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms18010048 · Cited by 75
Ströhlein, M. A., Lordick, F., Rüttinger, D., Grützner, K. U., Schemanski, O. C., Jäger, M., Lindhofer, H., Hennig, M., Jauch, K., Peschel, C., et al. (2011) · Onkologie · doi:10.1159/000324667 · Cited by 73
Rossi, E. A., Goldenberg, D. M., Cardillo, T. M., Stein, R., & Chang, C. (2009) · Blood · doi:10.1182/blood-2008-10-187138 · Cited by 72
Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule
Jakob, C. G., Edalji, R. P., Judge, R. A., DiGiammarino, E. L., Li, Y., Gu, J., & Ghayur, T. (2013) · mAbs · doi:10.4161/mabs.23977 · Cited by 72
Rossi, E. A., Goldenberg, D. M., Cardillo, T. M., Stein, R., & Chang, C. (2009) · Blood · doi:10.1182/blood-2009-06-228890 · Cited by 68
Mau‐Sørensen, M., Dittrich, C., Dienstmann, R., Lassen, U., Büchler, W., Martinius, H., & Tabernero, J. M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2728-5 · Cited by 68
World Bispecific Antibody Summit, September 27–28, 2011, Boston, MA
Dhimolea, E., & Reichert, J. M. (2012) · mAbs · doi:10.4161/mabs.4.1.18821 · Cited by 64
Gall, J. M., Davol, P. A., Grabert, R. C., Deaver, M., & Lum, L. G. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2005.01.007 · Cited by 63
Chemically programmed antibodies: Endothelin receptor targeting CovX-Bodies™
Doppalapudi, V. R., Tryder, N., Li, L., Aja, T., Griffith, D. A., Liao, F., Roxas, G., Ramprasad, M. P., Bradshaw, C. W., & Barbas, C. F. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.10.009 · Cited by 59
A revolutionary therapeutic approach for psoriasis: bispecific biological agents
Torres, T., Romanelli, M., & Chiricozzi, A. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1187130 · Cited by 54
VALONE, F. H., KAUFMAN, P. A., GUYRE, P. M., LEWIS, L. D., MEMOLI, V., ERNSTOFF, M. S., WELLS, W., BARTH, R., DEO, Y., FISHER, J., et al. (1995) · Journal of Hematotherapy · doi:10.1089/scd.1.1995.4.471 · Cited by 48
“NextGen” Biologics: Bispecific Antibodies and Emerging Clinical Results
Thakur, A. B., & Lum, L. G. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1150996 · Cited by 48
Rossi, E. A., Rossi, D. L., Stein, R., Goldenberg, D. M., & Chang, C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2126 · Cited by 46
The structure of dual-variable-domain immunoglobulin molecules alone and bound to antigen
Correia, I., Sung, J. J., Burton, R. E., Jakob, C. G., Carragher, B. O., Ghayur, T., & Radziejewski, C. H. (2013) · mAbs · doi:10.4161/mabs.24258 · Cited by 42
Pharmacokinetics of Bispecific Antibody
Chen, Y., & Xu, Y. C. (2017) · Current Pharmacology Reports · doi:10.1007/s40495-017-0090-5 · Cited by 41
A new class of bispecific antibodies to redirect T cells for cancer immunotherapy
Rossi, D. L., Rossi, E. A., Cardillo, T. M., Goldenberg, D. M., & Chang, C. (2013) · mAbs · doi:10.4161/mabs.27385 · Cited by 39
Potent Immunomodulatory Effects of the Trifunctional Antibody Catumaxomab
Goèré, D., Flament, C., Rusakiewicz, S., Poirier-Colame, V., Kepp, O., Martins, I., Pesquet, J., Eggermont, A. M. M., Elias, D. M., Chaput, N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4460 · Cited by 39
Lum, L. G., Thakur, A. B., Liu, Q., Deol, A., Al-Kadhimi, Z. S., Ayash, L. J., Abidi, M. H., Pray, C., Tomaszewski, E. N., Steele, P. A., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.03.010 · Cited by 38
Anti-CD22/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of Lupus
Rossi, E. A., Chang, C., & Goldenberg, D. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098315 · Cited by 37
Monoclonal antibodies in cancer therapy
Guo, Y., Hou, Q.-Y., & Wang, N. (2011) · Clinical Oncology and Cancer Research · doi:10.1007/s11805-011-0583-7 · Cited by 35
Sunwoo, H. H., Palaniyappan, A., Ganguly, A., Bhatnagar, P. K., Das, D., El‐Kadi, A. O. S., & Suresh, M. R. (2012) · Journal of Virological Methods · doi:10.1016/j.jviromet.2012.09.006 · Cited by 32
Pang, X., Ma, F., Zhang, P., Zhong, Y., Zhang, J., Wang, T., Zheng, G., Hou, X., Zhao, J., He, C., et al. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.122 · Cited by 32
Novel Targeted Therapies for Metastatic Melanoma
Iams, W. T., Sosman, J. A., & Chandra, S. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000242 · Cited by 31
Kosloski, M. P., Goss, S. L., Wang, S. X., Liu, J., Loebbert, R. W., Medema, J. K., Liu, W. Y., & Dutta, S. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.764 · Cited by 30
Fossati, M., Buzzonetti, A., Monego, G., Catzola, V., Scambia, G., Fattorossi, A., & Battaglia, A. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.06.003 · Cited by 28
Hybrid antibody‐mediated lysis of virus‐infected cells
Staerz, U. D., Yewdell, J. W., & Bevan, M. J. (1987) · European Journal of Immunology · doi:10.1002/eji.1830170422 · Cited by 24
Khatri, A., Goss, S. L., Jiang, P. X., Mansikka, H. T., & Othman, M. I. A. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0580-y · Cited by 22
Chen, Y., Qiao, Y., Zhao, X., Chen, H., Wang, Y., & Wang, Z. (2007) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00310-06 · Cited by 14
Chemically generated IgG2 bispecific antibodies through disulfide bridging
Patterson, J. T., Gros, E., Zhou, H., Atassi, G., Kerwin, L., Carmody, L., Zhu, T., Jones, B., Fu, Y., & Kaufmann, G. F. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.07.021 · Cited by 14
Bispecific Antibody-Mediated Detection of theStaphylococcus aureusThermonuclease
Wagstaffe, S. J., Hill, K. E., Williams, D. W., Randle, B. J., Thomas, D. W., Stephens, P., & Riley, D. J. (2012) · Analytical Chemistry · doi:10.1021/ac203403d · Cited by 13
Kontermann, R. E. (2015) · Springer eBooks · doi:10.1007/978-3-642-27841-9_658-2 · Cited by 11
Ma, Z., Li, T. X., Fu, W., Lei, C., & Hu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821584-5.00012-2 · Cited by 3
Cited by
Antibody–Drug Conjugates: A Comprehensive Review
Khongorzul, P., Ling, C. J., Khan, F. U., Ihsan, A. U., & Zhang, J. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0582 · Cited by 787
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
The pharmacology and therapeutic applications of monoclonal antibodies
Castelli, M. S., McGonigle, P., & Hornby, P. J. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.535 · Cited by 364
Therapies for rare diseases: therapeutic modalities, progress and challenges ahead
Tambuyzer, E., Vandendriessche, B., Austin, C. P., Brooks, P. J., Larsson, K., Miller Needleman, K. I., Valentine, J., Davies, K., Groft, S. C., Preti, R., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0049-9 · Cited by 357
Nanobody: outstanding features for diagnostic and therapeutic applications
Salvador, J.-P., Vilaplana, L., & Marco, M.-P. (2019) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-019-01633-4 · Cited by 350
Metadata
- Authors
- Sedykh, S., Prinz, V., Buneva, V., & Nevinsky, G.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2018-01
- Volume
- Volume 12
- Pages
- 195-208
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W2784605149
- Cited by
- 292
- References
- 127
- FWCI
- 24.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.